Overview

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study aim is to assess, if treosulfan pharmacokinetics are influenced by declined renal function and by race/ethnicity of patients. The study also aims to determine an appropriate safe dose of treosulfan, when patient's renal function is impaired. The participants of this study are undergoing allogenic hematopoietic stem cell transplantation for treatment of acute myeloid leukemia or myelodysplastic syndrome.
Phase:
Phase 1
Details
Lead Sponsor:
medac GmbH
Collaborator:
Synteract, Inc.
Treatments:
Fludarabine
Treosulfan